• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nevro Corp.

    2/14/24 3:47:31 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care
    Get the next $NVRO alert in real time by email
    SC 13G 1 armistice-nvro123123.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    NEVRO CORP

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    64157F103

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  64157F103
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    3,176,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    3,176,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,176,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.76%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  64157F103
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    3,176,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    3,176,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,176,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.76%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 64157F103
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    NEVRO CORP

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1800 Bridge Parkway

    Redwood City, CA 94065

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, $0.001 par value per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    64157F103

     

    CUSIP No.  64157F103
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 64157F103
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of December 31, 2023:

    Armistice Capital, LLC - 3,176,000

    Steven Boyd - 3,176,000  

    (b) Percent of Class as of December 31, 2023:

    Armistice Capital, LLC - 8.76%

    Steven Boyd - 8.76% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 3,176,000

    Steven Boyd - 3,176,000 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 3,176,000

    Steven Boyd - 3,176,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 36,262,589 Shares outstanding as of December 15, 2023, as reported on the Issuer’s Form S-3 filed with the Securities and Exchange Commission on December 28, 2023.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 64157F103
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 64157F103
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $NVRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVRO

    DatePrice TargetRatingAnalyst
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    12/3/2024$5.00Equal Weight
    Wells Fargo
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    8/9/2024Sell → Neutral
    Citigroup
    8/8/2024Underperform → Peer Perform
    Wolfe Research
    8/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $NVRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

      REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme

      1/21/25 4:30:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Nevro Enters Into Cooperation Agreement With Engaged Capital

      Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi

      2/21/24 4:06:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Jon R. Shear as Vice President, Corporate Development

      REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately.   "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and

      4/19/21 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

      REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.   "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a

      11/30/20 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Nevro Corp.

      15-12G - NEVRO CORP (0001444380) (Filer)

      4/14/25 8:30:09 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Nevro Corp.

      EFFECT - NEVRO CORP (0001444380) (Filer)

      4/8/25 12:15:06 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.

      SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)

      4/4/25 3:49:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $NVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $NVRO
    Financials

    Live finance-specific insights

    See more

    $NVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nevro upgraded by Jefferies with a new price target

      Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously

      2/10/25 7:02:54 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously

      2/7/25 8:27:53 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Nevro with a new price target

      Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00

      12/3/24 7:38:11 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nevro Corp.

      SC 13G - NEVRO CORP (0001444380) (Subject)

      12/4/24 4:27:18 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Nevro Corp.

      SC 13D/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:31:36 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nevro Corp.

      SC 13G/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:18:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Third-Quarter 2024 Financial Results

      Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

      11/11/24 4:05:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:33 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:35 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:38 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care